Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: March 7, 2000
Last updated: January 31, 2013
Last verified: May 2002
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: December 2001 (Final data collection date for primary outcome measure)